Gilead Sciences Inc. closed $7.05 short of its 52-week high ($98.90), which the company reached on November 11th.

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

In a report released today, Asthika Goonewardene from Truist Financial assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed yesterday at $92.38. Pick the ...

Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...